Epigenomics AG / Key word(s): Quarter Results/Quarter Results 2015-05-12 / 08:30 Press release Epigenomics AG Announces Q1 2015 Financial Results and Reports on Operational Highlights – Epigenomics reaches 99.5% adherence for Epi proColon(R) in the ADMIT Trial – BioChain starts to commercialize Epi proColon(R) in China – Epigenomics receives EUR 2.8 million grant from European […]
Category: Press Releases
12. May 2015
Epigenomics AG Announces Q1 2015 Financial Results and Reports on Operational Highlights
Read more
08. May 2015
Epigenomics Reaches 99.5 % Adherence for Epi proColon(R) in ADMIT Study
Epigenomics AG / Key word(s): Study/Study results 2015-05-08 / 09:06 Epigenomics Reaches 99.5 % Adherence for Epi proColon(R) in ADMIT Study Berlin, Germany, May 8, 2015 – Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) announces results from the ADMIT trial (ADherence to Minimally Invasive Testing – NCT02251782) for its non-invasive blood-based test for colorectal […]
29. April 2015
Epigenomics receives EUR 2.8m grant for Validation of Lung Cancer Biomarkers in Blood Plasma
Epigenomics AG / Key word(s): Miscellaneous/Miscellaneous 2015-04-29 / 09:30 Press release Epigenomics receives EUR 2.8m grant for Validation of Lung Cancer Biomarkers in Blood Plasma Berlin (Germany) and Germantown, MD (U.S.A.), April 29, 2015 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the Company will […]
25. March 2015
Epigenomics AG: Epigenomics Announces Completion of Enrollment in Epi proColon(R) ADMIT Trial
Epigenomics AG / Key word(s): Study 2015-03-25 / 07:30 Press release Epigenomics Announces Completion of Enrollment in Epi proColon(R) ADMIT Trial Berlin (Germany) and Germantown, MD (U.S.A.), March 25, 2015 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced the completion of subject enrollment into its ADMIT […]
25. March 2015
Epigenomics AG: Epigenomics AG Reports Results for the Financial Year Ended December 31, 2014 and Provides Outlook for 2015
Epigenomics AG / Key word(s): Final Results 2015-03-25 / 07:30 Press release Epigenomics AG Reports Results for the Financial Year Ended December 31, 2014 and Provides Outlook for 2015 Epi proColon(R) approved for commercialization in China US Approval: ADMIT trial fully enrolled; expected to report data in Q2 2015 Strong commitment from partners; EUR 4.2 […]
17. December 2014
Epigenomics AG: First Patients Enrolled in Epigenomics’ Epi proColon(R) ADMIT Study
Epigenomics AG / Key word(s): Study/Miscellaneous 17.12.2014 / 11:00 Berlin (Germany) and Germantown, MD (U.S.A.), December 17, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that first patients have been enrolled into its ADMIT trial (ADherence to Minimally Invasive Testing) for its noninvasive blood-based test […]